The United States Patent and Trademark Office has issued U.S. Patent No. 12,544,407 B2 , dated February 10, 2026, further strengthening FibroBiologics’ intellectual property portfolio in regenerative ...

FibroBiologics is planning a prospective, multicenter, open-label clinical trial evaluating the safety, tolerability, and efficacy of CYWC628 in treating refractory diabetic foot ulcers with up to 12 ...

FibroBiologics, Inc., a biotechnology company focused on developing therapies for chronic diseases using fibroblasts, announced that Dr. Chuo Fang presented research at the Society for Investigative ...

HOUSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development ...

FibroBiologics, Inc., a clinical-stage biotechnology company focused on developing therapies for chronic diseases through fibroblasts, announced an investor webinar scheduled for July 10, 2025, at ...

We believe it will take a positive biologic process created through fibroblast or a stem cell through immunotherapy or gene therapy. The three ways we think you'll be able to cure chronic diseases ...

A study by researchers and clinicians at the University of Eastern Finland and Helsinki University Hospital provides novel insight into the previously unknown effects of fibroblasts in regulating ...

USANewsGroup.com News Commentary -- The global cell therapy market is projected to surpass $8.2 billion in 2026, driven by a wave of clinical breakthroughs and manufacturing milestones reshaping ...